0K3W Stock Chart & Stats
$3.20
-$0.06(-1.05%)
At close: 4:00 PM EDT
$3.20
-$0.06(-1.05%)
Day’s Range― - ―
52-Week Range$2.75 - $8.58
Previous CloseN/A
Volume3.00
Average Volume (3M)2.46K
Market Cap
$404.60M
Enterprise Value$636.61
Total Cash (Recent Filing)$115.20M
Total Debt (Recent Filing)$210.50M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Nov 09, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend Yield1.22%
Share Statistics
EPS (TTM)-1.19
Shares Outstanding95,649,640
10 Day Avg. Volume2,224
30 Day Avg. Volume2,465
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.56
Price to Sales (P/S)0.70
P/FCF Ratio-22.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.05Price Target Upside-4.69% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering7
EPS Forecast (FY)-0.73
Revenue Forecast (FY)$777.82M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsConsistently high gross margins show that Myriad’s diagnostic products generate substantial value after direct testing costs. This provides a foundation for operating improvement, because stronger revenue growth or disciplined expense management could allow more gross profit to convert into earnings over time.
Positive Equity CushionPositive equity and manageable absolute leverage provide the company with a financial cushion while it works to improve profitability. Although leverage has increased, the balance sheet is not described as over-levered, supporting continued investment in its diagnostic platform and commercial operations.
Commercial Leadership ContinuityThe internal commercial promotion adds leadership continuity and relevant molecular-diagnostics and oncology experience to the growth function. Reaffirmed 2026 guidance also indicates management believes its operating trajectory remains achievable, supporting execution through the next several quarters.
Bears Say
Persistent Operating LossesSustained operating and net losses indicate that strong gross margins are currently outweighed by operating expenses. Unless Myriad improves scale, cost discipline, or revenue mix, the business may remain unable to convert diagnostic demand into durable earnings and internally funded growth.
Flat-to-Down RevenueRecent revenue contraction weakens the operating leverage available from Myriad’s high-margin testing model. A flat-to-down top line can make fixed commercial and infrastructure costs harder to absorb, delaying the path to profitability and increasing reliance on execution improvements to restore growth.
Fragile Free Cash FlowSlightly positive operating cash flow has not yet translated into consistently positive free cash flow. Continued volatility, including substantial prior-period outflows, limits the company’s ability to self-fund expansion, reduce debt, or withstand prolonged operating underperformance without added financial pressure.
Myriad Genetics News
0K3W FAQ
What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest share price was $2.75 and its highest was $8.58 in the past 12 months.
What is Myriad Genetics’s market cap?
Myriad Genetics’s market cap is $404.60M.
When is Myriad Genetics’s upcoming earnings report date?
Myriad Genetics’s upcoming earnings report date is Nov 09, 2026 which is in 39 days.
How were Myriad Genetics’s earnings last quarter?
Myriad Genetics released its earnings results on Jul 30, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.058 by -$0.192.
Is Myriad Genetics overvalued?
According to Wall Street analysts Myriad Genetics’s price is currently Overvalued.
Does Myriad Genetics pay dividends?
Myriad Genetics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 1.22%. See more information on Myriad Genetics dividends here
What is Myriad Genetics’s EPS estimate?
Myriad Genetics’s EPS estimate is -0.2.
How many shares outstanding does Myriad Genetics have?
Myriad Genetics has 95,649,640 shares outstanding.
What happened to Myriad Genetics’s price movement after its last earnings report?
Myriad Genetics reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.058. Following the earnings report the stock price went down -43.777%.
Which hedge fund is a major shareholder of Myriad Genetics?
Currently, no hedge funds are holding shares in GB:0K3W
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Myriad Genetics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$3.05 (-4.69% Downside)
$3.05 (-4.69% Downside)
Blogger Sentiment
Neutral
GB:0K3W Sentiment 60%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.67%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Myriad Genetics
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
0K3W Company Deck
0K3W Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful progress in core growth engines (double-digit hereditary cancer growth, robust GeneSight performance, solid gross margins and a deep product pipeline) and management reaffirmed full-year guidance and positive adjusted EBITDA expectations. Near-term pressures include a Q1 adjusted EBITDA loss, higher operating expense due to accelerated commercial hiring, and a notable prenatal revenue decline. Management is investing to drive back-half acceleration but execution (sales ramp, MRD adoption, payer reimbursement) will determine pace of recovery. On balance, the positives around market share gains, product launches and revenue guidance outweigh the short-term profitability and prenatal headwinds.View all GB:0K3W earnings summaries0K3W Stock 12 Month Forecast
Average Price Target
$3.05
▼(-4.69% Downside)